What is roflumilast?

What is Roflumilast?

Roflumilast is an oral, once-daily phosphodiesterase-4 (PDE4) inhibitor used to reduce exacerbations in patients with severe to very severe COPD who have chronic bronchitis and a history of frequent exacerbations despite optimal inhaled therapy. 1

Mechanism of Action

Roflumilast works by selectively inhibiting the PDE4 enzyme, which leads to increased intracellular cyclic AMP levels in lung cells 1. This anti-inflammatory mechanism is distinct from bronchodilators—roflumilast is NOT a bronchodilator and should not be used for acute breathing problems 1. The drug and its active metabolite (roflumilast N-oxide) both contribute to therapeutic effects, with the metabolite having a long half-life that enables once-daily dosing 1.

Clinical Indications

Primary Use: COPD Exacerbation Prevention

Roflumilast should be prescribed for patients with:

• Severe or very severe airflow obstruction (post-bronchodilator FEV1/FVC <0.70 and FEV1 <50% predicted) 2
• Chronic bronchitis symptoms (chronic cough and sputum production) 2, 3
• History of exacerbations despite optimal inhaled therapy (LABA, LAMA, or ICS combinations) 2

The 2017 ERS/ATS guidelines provide a conditional recommendation for roflumilast in this specific population, with moderate quality evidence 2. The 2017 GOLD strategy similarly recommends roflumilast for patients with chronic bronchitis, severe to very severe COPD, and exacerbation history 3.

Emerging Dermatologic Uses

Recent evidence shows roflumilast has been approved for dermatologic conditions:

• Seborrheic dermatitis (as 0.3% foam formulation) 4
• Psoriasis (oral formulation) 5
• Atopic dermatitis (as 0.15% cream, approved for children ≥6 years) 6

Clinical Efficacy in COPD

Benefits

• Reduces moderate and severe exacerbations: Rate ratio 0.85 (95% CI 0.78-0.91) for all exacerbations; rate ratio 0.76 (95% CI 0.60-0.95) for severe exacerbations requiring hospitalization 2
• Modestly improves lung function: Mean increase in post-bronchodilator FEV1 of +56 mL (95% CI +45 to +67 mL) 2
• Prolongs time to next exacerbation: Hazard ratio 0.88 (95% CI 0.81-0.96) 2
• No effect on mortality: Risk ratio 0.99 (95% CI 0.70-1.42), though studies had too few deaths to definitively assess this outcome 2

The exacerbation reduction is particularly pronounced in patients with severe disease and frequent exacerbations—this is the population that derives the most benefit 2, 7.

Adverse Effects Profile

Common Side Effects (Occur in 3-10% of patients)

Gastrointestinal effects are the most prominent:

• Diarrhea: 9.7% vs 2.7% placebo (risk ratio 3.96) 2
• Nausea: 4.8% vs 1.4% placebo (risk ratio 3.54) 2
• Weight loss: 8.4% vs 2.3% placebo (risk ratio 3.94) 2

Neuropsychiatric effects:

• Psychiatric disorders (anxiety, depression): 7.1% vs 3.5% placebo (risk ratio 2.13) 2
• Insomnia/sleep disturbance: 3.1% vs 1.1% placebo (risk ratio 2.88) 2

Treatment discontinuation: 14.9% vs 9.0% placebo discontinued due to adverse effects (risk ratio 1.80) 2

Critical Safety Warnings

Roflumilast carries FDA black box warnings for: 1

1. Psychiatric effects including suicidal ideation and behavior—patients must be monitored for mood changes, depression, anxiety, and suicidal thoughts
2. Weight loss—patients should have regular weight monitoring; discontinuation should be considered if unexplained significant weight loss occurs

Contraindications and Precautions

Absolute Contraindications

• Moderate to severe hepatic impairment (Child-Pugh B or C) 1

Use with Caution

• Mild hepatic impairment (Child-Pugh A): Consider risk-benefit carefully 1
• History of depression or psychiatric disorders: Requires close monitoring 1
• Underweight patients: Roflumilast should be avoided due to weight loss risk 3

Drug Interactions

Strong CYP450 enzyme inducers are NOT recommended with roflumilast as they reduce drug exposure and therapeutic effectiveness 1. These include:

• Rifampicin
• Phenobarbital
• Carbamazepine
• Phenytoin

Dosing and Administration

Standard dose: 500 mcg once daily, taken orally with or without food 1

No dose adjustment needed for:

• Geriatric patients 1
• Renal impairment 1

Clinical Positioning in COPD Treatment Algorithm

Roflumilast occupies a specific niche as add-on therapy:

1. First-line COPD therapy remains inhaled bronchodilators (LAMA preferred over LABA for exacerbation prevention) 2
2. For patients with blood eosinophils ≥300 cells/μL and exacerbations, add ICS to LABA/LAMA 8
3. For patients who continue to exacerbate despite triple therapy (LAMA/LABA/ICS), consider adding:
   • Roflumilast (if chronic bronchitis phenotype) 8
   • Macrolide therapy (if appropriate, no QT prolongation, no mycobacterial infection) 8
   • N-acetylcysteine (alternative option) 8

The 2023 Canadian Thoracic Society guidelines suggest roflumilast specifically for patients with chronic bronchitic phenotype who remain symptomatic and continue exacerbating despite optimal triple inhaled therapy 8.

Key Clinical Pearls

• Roflumilast is NOT a rescue medication—it takes time to show benefit and should be used for maintenance therapy only 1
• The drug works through anti-inflammatory mechanisms, not bronchodilation—don't expect immediate symptomatic relief 9
• Most adverse effects occur early in treatment—GI symptoms typically emerge within the first weeks 2
• Weight monitoring is mandatory—establish baseline weight and monitor regularly 1
• Screen for psychiatric history before initiating—this is a critical safety consideration 1
• Evidence is strongest in severe/very severe COPD with chronic bronchitis—efficacy in milder disease is unknown 2